Synthesis and characterization of a BODIPY conjugate of the BCR-ABL kinase inhibitor Tasigna® (Nilotinib): Evidence for transport of Tasigna® and its fluorescent derivative by ABC drug transporters

Tasigna® (Nilotinib) is a recently approved BCR-ABL kinase inhibitor by the Food and Drug Administration, which is indicated for the treatment of drug-resistant chronic myelogenous leukemia (CML). The efflux of tyrosine kinase inhibitors by ATP-binding cassette (ABC) drug transporters, which activel...

Descrición completa

Gardado en:
Detalles Bibliográficos
Main Authors: Shukla, Suneet, Skoumbourdis, Amanda P., Walsh, Martin J., Hartz, Anika M.S., Fung, King Leung, Wu, Chung-Pu, Gottesman, Michael M., Bauer, Björn, Thomas, Craig J., Ambudkar, Suresh V.
Formato: Artigo
Idioma:Inglês
Publicado: 2011
Assuntos:
Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC3148428/
https://ncbi.nlm.nih.gov/pubmed/21630681
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1021/mp2001022
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares